A new transatlantic working group for mergers in the pharmaceutical sector will provide an opportunity to build on existing cooperation among regulators in the US, UK, Canada and the European Union to help harmonize analysis, which has sometimes diverged in recent global deals.
The unified process is good news for parties, but